spacer
home > pmps > autumn 2017 > what now?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

What Now?

With the recent FDA announcement regarding a one-year delay in enforcement of the compliance policy for ‘Product Identified Requirements Under the Drug Supply Chain Security Act’ (DSCSA), many are left asking what this actually means for the wider pharmaceutical industry or their company’s initiatives. While the FDA communication specifically indicates a delay in enforcement, it is clear there is no delay of the law itself – a telling signal to the industry that this serialisation challenge is real.

Within the industry, much speculation and scepticism exists regarding what will happen in November 2017. Given the history of deadlines coming and going in California for most of a decade, followed by a national mandate passed by the US Congress (albeit watered down), many in the industry were left dubious that the government could realistically enforce the deadline. Furthermore, regulations and administration in Europe, Brazil and China have been walked back, morphed or changed over the past 12-18 months, adding to the industry’s doubts.

Over the past three to six months, the drumbeat of industry representatives appealing to the FDA for delayed enforcement has steadily increased. Despite best efforts, the industry as a whole is not prepared, and will not be so, for November of this year. While many leading pharma companies have actively progressed their serialisation initiatives, a large portion dragged their heels in a wait-and-see approach to enforcement. Equipment suppliers, third-party electronic product code information services providers, consultants and contract manufacturing organisations have raised concerns over the anticipated skyrocketing demand on resources as we approach the deadline. Since the beginning of 2017, those concerns have been fully realised. The industry simply does not have the collective resources to enable every pharma company to comply. Fortunately, the FDA listened to their concerns and acted accordingly. The industry has been given a reprieve – some breathing room – to get through the collective implementation. In the scope of work required for serialisation implementation, an additional 12 months is not a lot of time. It would be a very poor decision for any company to delay their current activity with the thought that the goal line has moved significantly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Justin Schroeder is Senior Executive Director of Global Marketing and Design at PCI Pharma Services. He is responsible for global marketing, creative package design and new account development, with a focus on the development and commercialisation of new products. Justin has over 20 years of experience in outsourced pharma services in various roles, including engineering, project management, marketing and development. He holds a Bachelor of Science from the School of Packaging at Michigan State University, US, and an MBA in marketing from Northern Illinois University, US. Justin is a certified Packaging Professional from the Institute of Packaging Professionals, US, and is the Vice Chairman of the US Healthcare Compliance Packaging Council. 
spacer
Justin Schroeder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is introducing a new internal cloud-based Quality Management System (QMS), Master Control. This new standardized, ISO compliant QMS will help BioIVT manage documentation, auditing, supplier and customer accounts, and risk across all locations. It will consolidate and replace a variety of computer- and paper-based document control systems located at existing and newly-acquired BioIVT sites in the US, Europe and Asia.
More info >>

White Papers

ConsulTech GmbH

ConsulTech GmbH

ConsulTech is a consulting company founded in 1992. Since then, we have been supporting biotech-nology, pharmaceutical and medical technology companies as well as research institutions with the entire process of setting-up and executing proposals for R&D projects. In projects funded by the European Commission, ConsulTech supports the coordinator by resuming administrative tasks allow-ing coordinators and partners to fully concentrate on the scientific and technical success of the pro-ject. We solve financial and administrative issues, organise meetings, take care of the timely delivery of milestones and reports and much more.
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement